Advaxis to Host Investigators Meeting for
ADXS11-001 Cervix Cancer Trial in Mumbai,
Twenty of India’s Leading Oncologists to Attend | Meetings Set for May 7 – 8, 2010
May 03, 2010 10:03 AM Eastern Daylight Time
NORTH BRUNSWICK, N.J.--(EON: Enhanced Online News)--Advaxis, Inc. (OTCBB: ADXS), the live,
attenuated Listeria monocytogenes (Lm) immunotherapy company, will host an investigator’s meeting in Mumbai,
India with twenty (20) of the country’s leading oncologists. The meeting is set for May 7-8, 2010 and will help
prepare for the initiation of a multicenter study of their lead compound, ADXS11-001 for the treatment of advanced,
metastatic cervix cancer in women who have failed cytotoxic therapy.
Investigators from Apollo Hospitals Research Foundation, Tata Memorial Centre, Chittaranjan National Cancer
Institute and other sites of clinical excellence will discuss Advaxis’ work, the experimental protocol to be conducted
and the execution of the clinical trial.
“Cervix cancer is a leading cause of mortality in Indian women,” said Advaxis Executive VP of Science and
Operations Dr. John Rothman. “If the efficacy signal we observed in our Phase 1 study in this patient population is
repeated in this larger study, then ADXS11-001 may represent an important agent for the treatment of a disease
state for which no effective therapy currently exists. We will also be investigating the use of our immunotherapy in
combination with chemotherapy in this trial. Combining immune and cytotoxic treatments is a very interesting and
important area of contemporary cancer research.”
Later during the week, Dr. John Rothman will lecture at the Chitteranjan National Cancer Institute and Chhatrapati
Shahuji Maharaj Medical University –formerly, King George's Medical University.
About the ADXS11-001 Immunotherapy
ADXS11-001 is a therapeutic vaccine that treats human papilloma virus (HPV) related tumors. Unlike marketed
prophylactic vaccines that require treatment prior to exposure to the virus, ADX